Why Is Pfizer Stock Paying You So Much To Wait?

Pfizer (PFE) throws off free cash worth 7.0% of its market value a year, against 4.4% for the median S&P 500 company. Everything turns on whether the cash holds. Management’s answer is a wait: it says it is well positioned to return to growth from 2029 onward. A 6.2% dividend yield over the past twelve months is what that wait pays.

How Does Pfizer Still Make This Much Cash?

Margins on medicines nobody else can sell yet. Operating margin over the trailing twelve months is 26.7%, against an S&P 500 median of 18.6% and Pfizer’s own three-year average of 18.7%. The June quarter leaned on Eliquis among others, in-line brands still inside their exclusivity.

Free cash flow over the trailing twelve months was $10.99 billion on $63.7 billion of revenue, positive in every rolling twelve-month period for three years. Steady in direction, if not in size.

Net debt of about $51.5 billion turns the same free cash flow into a 5.2% yield on enterprise value.

Why Is Pfizer’s Cash On Sale?

Pfizer has returned 20.7% over the past twelve months, ahead of the S&P 500, and at about $28 it sits 4% off its one-month high and 4% below its two-year high of $29.02. The discount is not in the share price—it is in the cash flow.

What is being discounted is the end of protection. Revenue has contracted at 5.2% a year across three years, and is down 0.2% over the past twelve months against an S&P 500 median revenue growth of 8.3%. The COVID business that filled the gap keeps shrinking: management cut its 2026 COVID revenue expectation to about $4 billion from $5 billion, and warned weak incidence could limit Paxlovid sales.

The rest is doing better: excluding COVID products it grew 5% operationally in the June quarter, and management raised full-year 2026 revenue guidance by $500 million at the midpoint.

Reported profit is another matter: the stock trades at 36.5 times earnings against an S&P 500 median of 22.6. That gap is where the pipeline’s misses land: the June quarter absorbed $4.3 billion of noncash impairments, mostly after a Phase 3 trial of sigvotatug vedotin missed its survival endpoint in lung cancer. None of it left the building, which is why cash and profit disagree.

Can Pfizer Replace What It Is Losing?

Pfizer is not standing still: cost programs target roughly $9.7 billion of net savings through 2029. The FDA widened Padcev’s approved use into muscle invasive bladder cancer in July, and that brand grew over 20% in the June quarter. In obesity, berobenatide is a monthly GLP-1 aiming at a first approval in 2028.

Scale is the problem. The newer products, recently launched or acquired, delivered $3.2 billion of revenue in the June quarter and grew 18% operationally, 27% excluding one-time items a year ago. Against roughly $15 billion of quarterly revenue, about a fifth of the company is growing fast while four-fifths waits on patents.

So watch whether those newer products keep that pace as the older brands roll off. If newer products sustain that pace, the current yield compensates for the wait; if they stumble, the market may simply be pricing in a permanently smaller company. Our Buy the Dip screen is where to check whether a pullback like this one is worth taking.

How Much Of Your Future Should One Cash Machine Carry?

A business generating this much cash is a real find, and it is still a single company. Concentration tends to arrive by accident rather than by decision. What your largest position would do to your net worth is exactly what the Trefis Wealth team computes, with the same rules-based systematic discipline that runs our High Quality Portfolio. Request a free vulnerability audit of your biggest positions.